Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

Nature Communications

Volumn 10, Issue 1, 2019, Pages

  van Kessel, Sebastiaan P ^a   Frye, Alexandra K ^a   El Gendy, Ahmed O ^a,d   Castejon, Maria ^a   Keshavarzian, Ali ^b   van Dijk, Gertjan ^c   El Aidy, Sahar ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Beni Suef University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE; LEVODOPA; METHYLDOPA; TYROSINE; TYROSINE DECARBOXYLASE; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DECARBOXYLATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; INTESTINE FLORA; LACTOBACILLUS; MALE; MICROBIAL METABOLISM; NONHUMAN; PARKINSON DISEASE; RAT; SMALL INTESTINE; STAPHYLOCOCCUS; AGED; ANIMAL; BACTERIUM; ENZYMOLOGY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIPARKINSON AGENTS; BACTERIA; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINE, SMALL; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RATS; TYROSINE DECARBOXYLASE;

EID: 85060132817     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-019-08294-y     Document Type: Article

References (41)

1. Kahrstrom, C. T., Pariente, N. & Weiss, U. Intestinal microbiota in health and disease. Nature 535, 47 (2016).
2. Yano, J. M. et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161, 264–276 (2015).
3. Mao, K. et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature 554, 255–259 (2018).
4. Pusceddu, M. M. et al. N-3 Polyunsaturated Fatty Acids (PUFAs) reverse the impact of early-life stress on the gut microbiota. PLoS ONE 10, e0139721 (2015).
5. El Aidy, S. et al. Temporal and spatial interplay of microbiota and intestinal mucosa drive establishment of immune homeostasis in conventionalized mice. Mucosal Immunol. 5, 567–579 (2012).
6. Kelly, J. R. et al. Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat. J. Psychiatr. Res. 82, 109–118 (2016).
7. Enright, E. F., Gahan, C. G., Joyce, S. A. & Griffin, B. T. The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016).
8. Niehues, M. & Hensel, A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J. Pharm. Pharmacol. 61, 1303–1307 (2009).
9. Pereira, P. A. B. et al. Oral and nasal microbiota in Parkinson’s disease. Park. Relat. Disord. 38, 61–67 (2017).
10. Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s Disease. Cell 167, 1469–1480.e1412 (2016).
11. Scheperjans, F. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov. Disord. 30, 350–358 (2014).
12. Deleu, D., Northway, M. G. & Hanssens, Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet. 41, 261–309 (2002).
13. Pinder, R. M. Possible dopamine derivatives capable of crossing the blood-brain barrier in relation to Parkinsonism. Nature 228, 358 (1970).
14. Katzenschlager, R. & Lees, A. J. Treatment of Parkinson’s disease: levodopa as the first choice. J. Neurol. 249(Suppl 2), Ii19–Ii24 (2002).
15. Goldin, B. R., Peppercorn, M. A. & Goldman, P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J. Pharmacol. Exp. Ther. 186, 160–166 (1973).
16. Gundert-Remy, U. et al. Intestinal absorption of levodopa in man. Eur. J. Clin. Pharmacol. 25, 69–72 (1983).
17. Perez, M. et al. Tyramine biosynthesis is transcriptionally induced at low pH and improves the fitness of Enterococcus faecalis in acidic environments. Appl. Microbiol. Biotechnol. 99, 3547–3558 (2015).
18. Zhu, H. et al. Crystal structure of tyrosine decarboxylase and identification of key residues involved in conformational swing and substrate binding. Sci. Rep. 6, 27779 (2016).
19. Zhang, K. & Ni, Y. Tyrosine decarboxylase from Lactobacillus brevis: soluble expression and characterization. Protein Expr. Purif. 94, 33–39 (2014).
20. Williams, B. B. et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell. Host. Microbe 16, 495–503 (2014).
21. Adibi, S. A. & Mercer, D. W. Protein digestion in human intestine as reflected in luminal, mucosal, and plasma amino acid concentrations after meals. J. Clin. Invest. 52, 1586–1594 (1973).
22. Bredberg, E., Lennernas, H. & Paalzow, L. Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration. Pharm. Res. 11, 549–555 (1994).
23. Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 25, 2649–2653 (2010).
24. Zoetendal, E. G. et al. The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J 6, 1415–1426 (2012).
25. El Aidy, S., van den Bogert, B. & Kleerebezem, M. The small intestine microbiota, nutritional modulation and relevance for health. Curr. Opin. Biotechnol. 32c, 14–20 (2014).
26. Pellegrini, C. et al. Gastric motor dysfunctions in Parkinson’s disease: current pre-clinical evidence. Park. Relat. Disord. 21, 1407–1414 (2015).
27. Valenzuela, J. E. & Dooley, C. P. Dopamine antagonists in the upper gastrointestinal tract. Scand. J. Gastroenterol. Suppl. 96, 127–136 (1984).
28. Gabrielli, M. et al. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 26, 889–892 (2011).
29. Fasano, A. et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 28, 1241–1249 (2013).
30. Richter, J. E. The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment. Gastroenterol. Clin. North Am. 36, 577–599 (2007).
31. Tan, A. H. et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Park. Relat. Disord. 20, 535–540 (2014).
32. Pfeiffer, R. Beyond here be dragons: SIBO in Parkinson’s disease. Mov. Disord. 28, 1764–1765 (2013).
33. Freedberg, D. E. et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 149, 883–885.e889 (2015).
34. Kempster, P. A. et al. Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130, 2123–2128 (2007).
35. Keshavarzian, A. et al. Colonic bacterial composition in Parkinson’s disease. Mov. Disord. 30, 1351–1360 (2015).
36. Koolhaas, J. M. et al. The resident-intruder paradigm: a standardized test for aggression, violence and social stress.J Vis. Exp. 4, e4367 (2013).
37. Auchtung, J. M., Robinson, C. D. & Britton, R. A. Cultivation of stable, reproducible microbial communities from different fecal donors using minibioreactor arrays (MBRAs). Microbiome 3, 42 (2015).
38. Zoetendal, E. G. et al. Isolation of DNA from bacterial samples of the human gastrointestinal tract. Nat. Protoc. 1, 870–873 (2006).
39. Torriani, S. et al. Rapid detection and quantification of tyrosine decarboxylase gene (tdc) and its expression in gram-positive bacteria associated with fermented foods using PCR-based methods. J. Food Prot. 71, 93–101 (2008).
40. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408 (2001).
41. Ganhao, M. F., Hattingh, J., Hurwitz, M. L. & Pitts, N. I. Evaluation of a simple plasma catecholamine extraction procedure prior to high-performance liquid chromatography and electrochemical detection. J. Chromatogr. 564, 55–66 (1991).